M&A
-
Eli Lilly Secures Experimental Cancer Therapy from Scorpion in Up-to-$2.5 Billion Deal
Eli Lilly announced its plan to acquire an experimental cancer therapy from Scorpion Therapeutics for a total consideration of up…
Read More » -
📰 Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion to Boost Cardiovascular Pipeline
The Swiss pharmaceutical giant Novartis has reached an agreement to acquire Anthos Therapeutics, a biopharmaceutical firm majority-owned by the life…
Read More » -
Merck Finalizes $3.4 Billion Acquisition, Enhancing Rare Tumor Portfolio
Merck has successfully completed its previously announced $3.4 billion acquisition of SpringWorks Therapeutics, a biopharmaceutical company based in Stamford, Connecticut.…
Read More » -
Roche Commits $3.5 Billion to Bolster MASH Portfolio via 89bio Acquisition
Roche has announced its plan to acquire 89bio, a San Francisco-based biotechnology firm, in a strategic move valued at approximately…
Read More » -
Novo Nordisk Secures Key MASH Therapy in $5.2 Billion Strategic Deal
Global pharmaceutical giant Novo Nordisk has significantly strengthened its position in the treatment landscape for Metabolic Dysfunction-associated Steatohepatitis (MASH) with…
Read More » -
Merck Finalizes $10 Billion Acquisition of Verona Pharma with No Competing Bids
Merck successfully completed its $10 billion acquisition of Verona Pharma last month, a deal notable for the absence of a…
Read More » -
Johnson & Johnson Expands Neuroscience Portfolio with $14.6 Billion Acquisition
Global healthcare leader Johnson & Johnson (J&J) commenced the J.P. Morgan Healthcare Conference by announcing its intent to acquire Intra-Cellular…
Read More » -
Pharmaceutical Giant Finalizes Acquisition of Obesity Drug Developer
The global pharmaceutical corporation Pfizer Inc. has announced the successful conclusion of its acquisition of the clinical-stage biotechnology firm, Metsera,…
Read More »